Abstract"Helicobacter pylori" have now been established as one of the sources of acute and chronic gastritis, duodenitis, gastric peptic ulcers and duodenal ulcers non-ulcer dyspepsia and Weird diseases and syndromes. It has been identified as a risk factor for gastric cancer and MALT-lymphoma. More than 90% of patients with duodenal ulcers and more than 70% of those with gastric ulcer and more than 80% patients with the gastric cancer have "" infection. Diagnosis of "" could be meddlesome like endoscopy and non-interfering such as urea-breath-test, detection of antigens in stool, detection of specific antibodies in patients' sera by means of serological tests--ELISA and Immunblott, molecular tests PCR and fluorescence-in situ-hybridization which also checks its resistance against clarithromycin and metronidazole. The treatment is still a challenge. There are many determinants for successful therapy like individual primary or secondary antibiotics resistance, mucosal drug concentration, patient compliance, side-effect profile and cost. Latest therapy relies on different mixtures of known antibiotics and anti-secretory agents. In a few studies, a standard triple therapy consisting of two antibiotics and a proton-pump inhibitor has been proposed as the first-line regimen. Bismuth-containing quadruple treatment, sequential treatment or a non-bismuth quadruple treatment (concomitant) are also an alternative therapy. Levofloxacin containing triple treatment are recommended as rescue treatment for infection of "" after defeat of first-line therapy. Achieving a successful "H. pylori" vaccine is a feasible route towards treatment which will have synergistic or additive consequence against "H. pylori".